These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16952615)

  • 1. Metastatic prostate cancer-does treatment of the primary tumor matter?
    Swanson G; Thompson I; Basler J; Crawford ED
    J Urol; 2006 Oct; 176(4 Pt 1):1292-8. PubMed ID: 16952615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Locally advanced prostate cancer: definition, prognosis and treatment].
    Plantade A; Massard C; de Crevoisier R; Fizazi K
    Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The case for adjuvant therapy for prostate cancer.
    Glodé LM
    J Urol; 2006 Dec; 176(6 Pt 2):S30-3. PubMed ID: 17084163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving treatment paradigms for locally advanced and metastatic prostate cancer.
    Dorff TB; Quek ML; Daneshmand S; Pinski J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1639-51. PubMed ID: 17134367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current controversies in the treatment of high-risk prostate cancer.
    Mitchell RE; Chang SS
    Curr Opin Urol; 2008 May; 18(3):263-8. PubMed ID: 18382235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
    Amato RJ; Teh BS; Henary H; Khan M; Saxena S
    Urol Oncol; 2009; 27(2):165-9. PubMed ID: 18367115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcoma of the prostate: a single institutional review.
    Janet NL; May AW; Akins RS
    Am J Clin Oncol; 2009 Feb; 32(1):27-9. PubMed ID: 19194120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
    Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer update: 2006.
    Lin AM; Small EJ
    Curr Opin Oncol; 2007 May; 19(3):229-33. PubMed ID: 17414641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of locally advanced prostate cancer: past, present, future.
    Swanson GP
    J Urol; 2006 Dec; 176(6 Pt 2):S34-41. PubMed ID: 17084164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study.
    Gontero P; Marchioro G; Pisani R; Zaramella S; Sogni F; Kocjancic E; Mondaini N; Bonvini D; Tizzani A; Frea B
    Eur Urol; 2007 Apr; 51(4):922-9; discussion 929-30. PubMed ID: 17049718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.